Opinion/decision on a Paediatric investigation plan (PIP): Ibrexafungerp citrate, decision type: , therapeutic area: , PIP number: P/0370/2022

Opinion/decision on a Paediatric investigation plan (PIP): Aspaveli,Pegcetacoplan, decision type: , therapeutic area: , PIP number: P/0403/2022

Opinion/decision on a Paediatric investigation plan (PIP): Clazakizumab, decision type: , therapeutic area: , PIP number: P/0393/2022

Fenoterol / ipratropium : List of nationally authorised medicinal products - PSUSA/00001367/202302

Human medicines European public assessment report (EPAR): Hepcludex, bulevirtide, Hepatitis D, Chronic, Date of authorisation: 31/07/2020, Revision: 11, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Momelotinib, decision type: , therapeutic area: , PIP number: P/0157/2015

Opinion/decision on a Paediatric investigation plan (PIP): Momelotinib, decision type: , therapeutic area: , PIP number: P/0249/2019

Opinion/decision on a Paediatric investigation plan (PIP): Marstacimab, decision type: , therapeutic area: , PIP number: P/0443/2022

Opinion/decision on a Paediatric investigation plan (PIP): Monovalent, recombinant, replication-incompetent human adenovirus serotype 26-vectored vaccine encoding the pre-fusion conformation-stabilised F protein derived from the RSV A2 strain, decision type: , therapeutic area: , PIP number: P/0442/2022

Human medicines European public assessment report (EPAR): Imatinib Teva, imatinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Myelodysplastic-Myeloproliferative Diseases;Hypereosinophilic Syndrome;Dermatofibrosarcoma, Date of authorisation: 07/01/2013, Revision: 19, Status: Authorised